Hologic’s HOLX acquisition of Biotheranostics in 2021 accelerated its entry into a large, fast-growing oncology adjacency. The business also carries higher margins than the company’s legacy service ...
Within the study population, approximately 49% of patients were lost to follow-up or did not complete adjuvant treatment through 5 years. Fifty-two percent of patients switched to a different ...
Immune checkpoint inhibitors (ICPis) have proven extremely efficacious in cancer therapy but also lead to a plethora of immune-related adverse events (irAEs). The endocrine irAEs are not only quite ...
Clinical trial enrollment has dropped massively across the world with endocrine and cardiovascular tests being the hardest hit. This is according to a new breakdown from Medidata (PDF), now owned by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results